Vitruvias Therapeutics recalls 3,655 thyroid tablets in the U.S.
Published · Updated
AI-generated summary of the coverage listed below: The U.S. Food and Drug Administration has upgraded a recall of Vitruvias Therapeutics’ thyroid tablets to a Class I status, indicating a high risk of serious health problems. The recall covers about 3,655 units from a single lot. The tablets are considered superpotent and could trigger heart problems in patients. The move aims to prevent potential adverse health outcomes and protect consumers.
Covered by 3 outlets across the spectrum: 0% left, 67% center, 33% right.
Who is covering this story
- Center (2): Economic Times, Mint
- Right-leaning (1): Sunday Guardian
Sources
- Vitruvias Therapeutics thyroid tablet recalled in US — Economic Times (center)
- Vitruvias Therapeutics Thyroid Drug Recall Elevated to FDA’s Highest-Risk Class I Level -What It Means — Sunday Guardian (right-leaning)
- FDA upgrades Vitruvias Therapeutics recall: Superpotent thyroid tablets could trigger heart problems; who is at risk? — Mint (center)